ACE-i
The main pharmacodynamic difference between angiotensin-converting       enzyme-inhibitors (ACE-i) and angiotensin-II-receptor antagonists (AII-r) is that       ACE-i increase levels of bradykinin, which, in addition to vasodilation, may       cause a decrease in insulin resistance.
The main pharmacodynamic difference between angiotensin-converting       enzyme-inhibitors (ACE-i) and angiotensin-II-receptor antagonists (AII-r) is that        @SUBJECT$   @PREDICAT$  levels of  @OBJECT$ , which, in addition to vasodilation, may       cause a decrease in insulin resistance.